Global biomaterials market at $88.4 billion by 2017

Image source: biomaterials.org

The global biomaterial market is estimated to reach $88.4 billion by 2017 from $44.0 billion in 2012, growing at a CAGR of 15%, according to a recent study, "The Global Biomaterials Market with Forecasts to 2017" released by Research and Markets. 

Increased investments, funding and grants by government bodies worldwide, incessant rise in the number of collaborations, conferences and research-related activities, technological advancements, increasing applications of biomaterials, and growing number of elderly people are the major factors propelling the growth of the biomaterial market globally. Immunological and inflammatory reactions, stringent regulatory systems, issue of fracture fatigue and wear and reimbursement concerns are the major deterrents curbing the biomaterial market.

The global biomaterial market witnesses a plethora of growth opportunities. Novel developments of biomaterial for wound healing, plastic surgery, tissue engineering, ophthalmology, and neurology, colossal pool of cardiac patients in Asia, rise of biomaterial market in China and Taiwan, and increased conferences and research-related activities in RoW countries are major factors influencing the growth of the biomaterial market. The burning issues affecting the growth of biomaterial market are challenges to tissue engineering and effect on suppliers by the Biomaterials Access Assurance Act.

The global biomaterial market is dominated by North America, followed by Europe, Asia, and Rest of the World (RoW). North America will continue to lead the biomaterial market in the years to come, followed by Europe. North American market growth is likely to be driven by increasing government investments in biomaterial sector, reimbursements offered by Centers for Medicare and Medicaid Services (CMS) and rising aging population who are the main consumers of biomaterials. The North American biomaterial market is expected to receive a significant push due to phenomenal increase in new products such as botox, botulinum toxins, and hyaluronic-based injectables.